Today Columbus Venture Partners announces the creation of Syngoi Technologies, a biotechnology company engaged in the production of synthetic DNA through a new enzymatic process, owned by the company, that addresses the needs of advanced therapies where DNA is the fundamental starting material. This is the case of gene therapy and mRNA-based vaccines, emerging therapeutic strategies where manufacturing is an...Read more
With the new investment fund, the managers plan to build two new plants in San Sebastian Columbus Venture Partners already has its second fund ready to invest in companies related to health sciences. It is in the registration phase at the National Securities Market Commission (CNMV) and will be operational shortly. The expected volume is 70 million euros, reports Expansión. According to...Read more
Latest innovations and first-hand business models
🟦🟨 From resilience to transformation Ukraine aims to accelerate the modernisation of economy and favour a transformation of the country allowing smoother integration and access into the European and G7 markets Government's phased reconstruction plan with 850 projects. Of these, 580 projects with $350 billion value are planned for 2023-2025, and 270 projects with $400 billion value are scheduled for 2026-2032 FULL PLAN: https://www.urc2022.com/urc2022-recovery-plan EU...Read more
